WiZeCell

Stent Design

WiZeCell, our proprietary stent design is paradigm shift in cardiovascular stenting. The design’s sixth generation, the EluNIR drug eluting stent, relieves physicians from compromising between vessel conformability, scaffolding integrity, uniform drug distribution and radial support by offering an integrated design maximizing all benefits simultaneously.

Low footprint variable width design

40µm ultra narrow struts provides flexibility and conformability

Optimal scaffolding area provides uniform support and drug elution and prevents tissue prolapse

72µm struts provides excellent radial strength

Stent Performance

Medinol’s WiZeCell architecture, with its unique combination of flexible 40µm narrow struts and 72µm supportive struts, minimizes variations in cell size, even in sharp vessel bends and during systolic cycles. This highly-uniform scaffolding is designed for optimal scaffolding and uniform drug dosing while preventing tissue prolapse

  • Natural vessel curvature and myocardial contractions test the limits of stent design and scaffolding integrity. WiZeCell’s optimized cell size ensures uniform scaffolding and prevents tissue prolapse and strut overlap
  • Medinol’s WiZeCell architecture, with its unique combination of flexible ultra-narrow struts and narrow supportive struts, minimizes variations in inter-strut gaps, even in sharp vessel bends and during systolic cycles
  • The highly-uniform scaffolding conforms to vessel anatomy and moves dynamically with the vessel, reducing trauma to vessel-wall tissue and the resulting inflammation that can lead to restenosis

Medinol WiZeCell

Competitor A

Competitor B

Competitor C

Note the WiZeCell design (left) enabling uniform scaffolding while other stent designs enable large openings, contributing to tissue prolapse and potentially restenosis